Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

BACKGROUND: This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360. METHODS: Healthy US adults (N = 164) randomized int...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Neil, Bockstal, Viki, Bart, Stephan, Luhn, Kerstin, Robinson, Cynthia, Gaddah, Auguste, Callendret, Benoit, Douoguih, Macaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441209/
https://www.ncbi.nlm.nih.gov/pubmed/32939546
http://dx.doi.org/10.1093/infdis/jiaa586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441209/
https://www.ncbi.nlm.nih.gov/pubmed/32939546
http://dx.doi.org/10.1093/infdis/jiaa586

Ejemplares similares